DXCM - DexCom, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
129.03
-13.13 (-9.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close142.16
Open140.68
Bid129.10 x 800
Ask132.90 x 1800
Day's Range127.90 - 140.95
52 Week Range68.86 - 156.16
Volume3,946,620
Avg. Volume1,330,527
Market Cap11.613B
Beta (3Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)-1.44
Earnings DateApr 30, 2019 - May 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est161.88
Trade prices are not sourced from all markets
  • DexCom (DXCM) Down 11.8% Since Last Earnings Report: Can It Rebound?
    Zacksyesterday

    DexCom (DXCM) Down 11.8% Since Last Earnings Report: Can It Rebound?

    DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • HMS Holdings Gains on PI & TPM Solutions, Competition Rife
    Zacks2 days ago

    HMS Holdings Gains on PI & TPM Solutions, Competition Rife

    HMS Holdings is consistently boosting margins and profitability on product-yield enhancements and process improvements.

  • Here's Why You Should Retain Ecolab Stock in Your Portfolio
    Zacks2 days ago

    Here's Why You Should Retain Ecolab Stock in Your Portfolio

    A solid guidance for 2019 and broad product spectrum will provide Ecolab (ECL) a competitive edge in the MedTech space.

  • Here's Why DexCom Shares Are Dropping Today
    Motley Fool2 days ago

    Here's Why DexCom Shares Are Dropping Today

    The stock falls hard after a short-seller takes aim at the company.

  • DexCom, comScore, Lululemon, Nike and Under Armour highlighted as Zacks Bull and Bear of the Day
    Zacks2 days ago

    DexCom, comScore, Lululemon, Nike and Under Armour highlighted as Zacks Bull and Bear of the Day

    DexCom, comScore, Lululemon, Nike and Under Armour highlighted as Zacks Bull and Bear of the Day

  • Bull of the Day: DexCom (DXCM)
    Zacks3 days ago

    Bull of the Day: DexCom (DXCM)

    Bull of the Day: DexCom (DXCM)

  • Here's Why You Should Hold on to Cerner (CERN) Stock for Now
    Zacks3 days ago

    Here's Why You Should Hold on to Cerner (CERN) Stock for Now

    Recently, Cerner (CERN) expanded its reach in the Alabama rural health care market through a new collaboration.

  • Benzinga3 days ago

    Spruce Point: Dexcom Could Fall 45-60%

    DexCom, Inc. (NASDAQ: DXCM ) shares are trading lower after a new report from Spruce Point Capital argued the stock could fall 45-60 percent. The San Diego-based company manufacturers continuous glucose ...

  • Here’s What the Apple Watch Means for AAPL Stock
    InvestorPlace3 days ago

    Here’s What the Apple Watch Means for AAPL Stock

    It's become increasingly clear over the past few months that Apple (NASDAQ:AAPL) can no longer rely on the iPhone alone. That realization initially tanked Apple stock, which dropped nearly 40% between early October and late December. Of late, however, investors have become more comfortable with that pivot: AAPL stock already has gained nearly 20% so far in 2019.Source: Shutterstock The bull case for Apple stock, as Luke Lango argued this month, is that services revenue can offset hardware pressure. With Apple stock still cheap (it trades at less than 15x forward earnings), even modest growth is enough.Add in the fact that Apple still has more cash on its balance sheet than any company in history, and it doesn't take smashing success for AAPL to move higher.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe bear case, which I laid out in detail last year, is that the iPhone simply is too important. The product still drives 60% of revenue. And with Apple's market capitalization nearly $900 billion, what would be a hit for another company barely moves the needle for Apple. * 7 Beaten-Up Stocks to Buy as They Reverse Course The Apple Watch is an interesting microcosm of that bull/bear debate. And news this week of a landmark study involving the product adds an intriguing layer to the argument.From one standpoint, the Apple Watch could be a key part of the transformation of Apple and AAPL stock. From another, it hardly matters at all. The Apple Watch StudyOn Monday, researchers from Apple and Stanford Medicine released the results of a massive study involving the Apple Watch. Some 419,000 subjects participated over eight months. Those individuals wore the target smartwatches with the capability to detect abnormal heartbeats.The results aren't conclusive. Roughly 0.5% of the participants received notice of an irregular pattern. Unsurprisingly, the rate was higher in older patients.Of those who received a notice, only about 20% followed up by wearing a patch to confirm the diagnosis. Of that group, 34% received a confirmed diagnosis. But in a smaller group of subjects who wore both a patch and the Apple Watch, 84% of atrial fibrillation cases detected by the path were also picked up by the Watch.On the whole, the study does seem like good news for Apple (and for patients). There are concerns about false positives from the technology. However, the innovation is constantly improving and will benefit from further tweaking. As one cardiologist told CNBC, the results were "moderately good for a screening tool, but not amazing." That description could change over time, and more studies should give a better understanding of just how effective the Apple Watch is.The study doesn't prove that the Apple Watch can be a successful cardiac screening tool, at least not yet. A two-in-three false positive rate might be too problematic for some (or most) doctors. But at the least, the study does show that Apple might be on the right path in terms of developing life-saving -- and profitable -- technology. Does It Matter for AAPL Stock?From an investment standpoint, the question is whether even success here is enough. Again, this is a nearly $900 billion company. Fitbit (NYSE:FIT), whose smartwatch category the Apple Watch has taken over, has an enterprise value well under $1 billion.Apple hasn't broken out its smartwatch revenue. But sales of "other products" -- including Apple Watch, AirPods, Apple TV, Beats and other smaller lines -- in fiscal year 2018 were $17.4 billion, according to the 10-K. CFO Luca Maestri last year said AirPods and Apple Watch combined were driving over $10 billion annually in revenue.That's a big number. But the revenue from other products (now called "Wearables, Home and Accessories") still is about 7% of trailing-twelve-month revenue after driving 8.7% of first-quarter sales. Assuming its smartwatch revenue is $7-8 billion (roughly half of that category), it still drives maybe 3% of total corporate revenue. Even modest declines in iPhone revenue will more than offset growth in the Apple Watch. The Services Case for Apple StockSo it's easy perhaps to argue that the smartwatch division simply isn't enough. But where the story gets interesting is not just in hardware sales, but how the company can monetize the services side of the product. Healthcare giant Johnson & Johnson (NYSE:JNJ) is joining in the next controlled study of the Apple Watch. And the product itself could be the tip of the spear in the company's healthcare strategy.Back in January, Dana Blankenhorn detailed that strategy and the ways in which AAPL stock could profit from healthcare services. Monitoring revenues could be large. DexCom (NASDAQ:DXCM) is a $13 billion company built off the back of a continuous glucose monitoring system for diabetes. Other tech giants, including Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL), are looking to profit from the intersection of medicine and technology. However, the Apple Watch puts the company into millions of homes, a huge head start.I still question whether it's enough. Even the development of a DexCom-sized business adds less than 2% to Apple's market capitalization. But combined with efforts elsewhere in services, in content, and through share buybacks, there's an argument that Apple can keep profits intact in the near-term before eventually driving growth again.That's the strategy needed to keep AAPL stock moving higher, particularly with the year-to-date rally. How investors view the potential of the Apple Watch given recent developments might show how they will view the possibilities of Apple's larger pivot away from its reliance on hardware … and just how successful that strategy is going to be.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Specialty Retail ETFs to Buy the Industry's Disruption * 5 Stocks To Buy for the Happiest Employees * 3 Out-of-Favor Consumer Stocks to Buy Compare Brokers The post Here's What the Apple Watch Means for AAPL Stock appeared first on InvestorPlace.

  • Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
    Zacks4 days ago

    Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?

    Is (DXCM) Outperforming Other Medical Stocks This Year?

  • Inogen's Prospects in Europe Solid Amid Trade-Related Tension
    Zacks5 days ago

    Inogen's Prospects in Europe Solid Amid Trade-Related Tension

    Inogen's (INGN) business-to-business unit sees strength in Europe.

  • Veeva Systems (VEEV) Gains From Solid Results for Fiscal Q4
    Zacks7 days ago

    Veeva Systems (VEEV) Gains From Solid Results for Fiscal Q4

    Veeva Systems' (VEEV) broad spectrum of products include Veeva Vault, Veeva CRM, Veeva Network and Veeva OpenData.

  • 3 Top Diabetes Stocks to Watch in March
    Motley Fool8 days ago

    3 Top Diabetes Stocks to Watch in March

    Keep your eyes on these three hot diabetes stocks this month.

  • Zacks12 days ago

    Tech Snaps Market Out of Slump

    Tech Snaps Market Out of Slump

  • Varian & Tata Trust Tie Up to Boost Radiotherapy in India
    Zacks13 days ago

    Varian & Tata Trust Tie Up to Boost Radiotherapy in India

    Varian's (VAR) three-year deal with Tata Trust is likely to fortify its foothold in the Asia-Pacific radiotherapy space.

  • The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom
    Zacks13 days ago

    The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom

    The Zacks Analyst Blog Highlights: Jazz Pharmaceuticals, Lululemon Athletica, ABIOMED and DexCom

  • The Best And Worst Stocks of the 10-Year Bull Market
    Zacks13 days ago

    The Best And Worst Stocks of the 10-Year Bull Market

    We highlight some of the best and worst stocks over the bull market's 10 years.

  • HOLX vs DXCM: Which MedTech Stock is a Better Investment Pick?
    Zacks14 days ago

    HOLX vs DXCM: Which MedTech Stock is a Better Investment Pick?

    DexCom (DXCM) looks stronger than Hologic (HOLX) when it comes to current-year earnings and revenue projections as well as fundamentals.

  • Is DexCom a Buy?
    Motley Fool16 days ago

    Is DexCom a Buy?

    The diabetes-focused darling has been a monster winner. Is it too late to get in?

  • Align Technology-Benco Dental Deal to Expand iTero Reach
    Zacks16 days ago

    Align Technology-Benco Dental Deal to Expand iTero Reach

    Align Technology (ALGN) adopts initiatives to boost top-line contributions from iTero Intraoral scanners.

  • GNC Holdings to Expand Portfolio With Alani Nutrition Deal
    Zacks17 days ago

    GNC Holdings to Expand Portfolio With Alani Nutrition Deal

    With Alani Nutrition being a women-focused supplement brand, it is believed that the partnership might help GNC Holdings (GNC) widen its customer base.

  • Tandem's Global Growth a Boost, Operating Losses a Bane
    Zacks17 days ago

    Tandem's Global Growth a Boost, Operating Losses a Bane

    Tandem's (TNDM) t:slim X2 Insulin Pump clinching a commercial license in Canada during Q4 is a tailwind.

  • GNC Forms Joint Venture With IVC to Improve Cost Efficiency
    Zacks18 days ago

    GNC Forms Joint Venture With IVC to Improve Cost Efficiency

    The joint venture is set to manufacture the products produced by GNC Holdings' (GNC) Nutra manufacturing facility.

  • Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now
    Zacks20 days ago

    Here's Why You Must Add Hologic (HOLX) to Your Portfolio Now

    Hologic's (HOLX) management is impressed with continued growth in the core Molecular Diagnostics sub-segment.

  • Hologic (HOLX) Receives Global Nods for Omni Hysteroscope
    Zacks20 days ago

    Hologic (HOLX) Receives Global Nods for Omni Hysteroscope

    Hologic's (HOLX) receipt of approvals for Omni Hysteroscope in Canada and Europe is expected to boost the GYN Surgical arm.